AstraZeneca Stock Jumps 3.5%: Cancer Drugs Beat — and a $2 Billion Overhaul

AstraZeneca shares rose about 3% in London and 3.5% in U.S. premarket trading on Friday, October 30, 2026, after the British drugmaker beat third-quarter expectations and unveiled a $2 billion restructuring to fund its drug pipeline. Total revenue rose 7% at constant exchange rates to $16.21 billion, while core earnings per share rose 19% at constant exchange rates to $2.79.

What happened

AstraZeneca reported third-quarter total revenue of $16.21 billion, ahead of the $15.99 billion consensus forecast cited by Dow Jones, and net profit of $3.12 billion, up from $2.535 billion a year earlier. Reported earnings per share rose 26% at constant exchange rates to $2.02, and reported operating profit rose 26% to about $4.39 billion. For the first nine months of 2026, total revenue reached $46.88 billion, up 7% at constant exchange rates, with core earnings per share up 14% to $8.00.

The beat was driven mainly by oncology. The company said double-digit growth across oncology, respiratory and immunology, and rare disease offset headwinds from Farxiga and Brilinta losing exclusivity and from volume-based procurement in China. One detailed breakdown put oncology revenue up 17% in the quarter to $7.8 billion, helped by the cancer immunotherapy Imfinzi and the breast cancer drug Enhertu. Analysts at Jefferies added that Tagrisso beat consensus by 4% and Imfinzi by 1%, while alliance revenue, which includes Enhertu, came in 8% ahead.

Why it is blowing up

Two things landed at once. First, the profit beat was bigger than the revenue beat. Jefferies noted core operating profit of $5.86 billion was 8% ahead of consensus, with a core operating margin of 36.1% that was about 230 basis points above consensus, helped by research and selling costs coming in below forecasts. The broker called the quality of the revenue encouraging and said the margin performance bodes well for 2027.

Second, AstraZeneca used the results to launch a major restructuring. The programme carries up to $2 billion in one-time charges and is expected to generate about $1.5 billion in annual benefits, freeing money to reinvest in the pipeline. The company is aiming to grow beyond its existing ambition of $80 billion in annual revenue by 2030, even as patent protection expires for several big medicines in the early 2030s. That combination — a clean beat today plus a funded plan for growth after patent expiries — is what lifted the shares while broader European technology stocks were falling on renewed worries about artificial intelligence spending.

Key facts

Revenue: $16.21 billion in Q3, up 7% at constant exchange rates, versus a $15.99 billion consensus forecast.

Core earnings: $2.79 per share, up 19% at constant exchange rates, beating analyst expectations.

Net profit: $3.12 billion, up from $2.535 billion in the same quarter a year earlier.

Oncology: The largest division grew strongly, with Imfinzi, Enhertu and Tagrisso among the products cited by analysts as beating forecasts.

Restructuring: Up to $2 billion in charges for about $1.5 billion in annual benefits, to be reinvested in the drug pipeline.

Guidance: Reconfirmed for 2026 — total revenue up by a mid-to-high single-digit percentage and core earnings per share up by a low double-digit percentage at constant exchange rates, with a core tax rate of 18% to 22%.

What is next

AstraZeneca still faces the pressures it flagged in the quarter: cardiovascular, renal and metabolism revenue fell as Farxiga and Brilinta face generic competition, and some pipeline programmes have been discontinued or set back this year. Jefferies also cautioned that some of the third-quarter cost saving may be timing, because research spending usually steps up in the fourth quarter. The next scheduled test is the full-year and fourth-quarter results on February 9, 2027, when investors will look for progress on the restructuring, the size of the savings actually delivered, and whether oncology can keep offsetting the patent losses. This report describes what happened and why markets reacted; it is not a recommendation to buy, sell or hold any security.

Sources

AstraZeneca — 9M and Q3 2026 results
Morningstar / Dow Jones — AstraZeneca posts revenue, profit growth on strong cancer-drug sales
Seeking Alpha — AstraZeneca Q3 profit beats estimates as cancer drug sales drive growth
The Times — AstraZeneca announces $2bn restructuring to invest in drugs pipeline
The Market Reporter — AstraZeneca shares rise 3% as Jefferies says record margin bodes well for 2027

FAQ

Why did AstraZeneca stock jump on October 30, 2026?

Shares rose about 3% in London and 3.5% in U.S. premarket trading after Q3 revenue and core earnings beat forecasts and the company unveiled a $2 billion restructuring to fund its pipeline.

What were AstraZeneca's Q3 2026 results?

Total revenue was $16.21 billion, up 7% at constant exchange rates, core earnings per share were $2.79, up 19% at constant exchange rates, and net profit was $3.12 billion.

What is AstraZeneca's $2 billion restructuring?

It is a multi-year programme with up to $2 billion in one-time charges that is expected to generate about $1.5 billion in annual benefits, to be reinvested in developing new medicines.

Did AstraZeneca change its 2026 guidance?

No. It reconfirmed guidance for total revenue growth of a mid-to-high single-digit percentage and core earnings per share growth of a low double-digit percentage at constant exchange rates.